Study Group: Infectious Diseases Physicians (US)
Council Members in this Study Group: 885
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Donald Thea
Professor of International Health
Boston University School of Medicine - CC
Donald Thea, MD, is a Professor of International Health at Boston University School of Public Health, Massachusetts. He has also been the Director of the Clinical Research Unit. This unit oversees a portfolio of international clinical research in the...
- Steven Fine
Physician
UNIVERSITY OF ROCHESTER MEDICAL CENTERSteven Fine, MD, PhD, is an HIV and Infectious Disease specialist, an Assistant Professor in the Infectious Disease Unit at the University of Rochester Medical Center, and Staff Physician at Community Health Network. His clinical expertise is all aspects...
- Donald Graham
Department Chair of Infectious Diseases
SPRINGFIELD CLINIC LLPDonald Graham, MD, is Chairman of the Department of Infectious Diseases at the Springfield Clinic in Illinois. He is also Clinical Professor of Medicine at Southern Illinois University School of Medicine. Dr. Graham serves as Medical Advisor of the Sangamon...
Jeffrey WeinbergDirector of Clinical Research - Dermatology
ST LUKE'S-ROOSEVELT HOSPITAL CENTERJeffrey Weinberg, MD, is Director of the Clinical Research Center in the Department of Dermatology at St. Luke's-Roosevelt Hospital Center and Beth Israel Medical Center, both of which are part of the Continuum Health Partners hospital system in New York....
Barry SchechterDirector of Corneal and External Diseases
FLORIDA EYE MICROSURGICAL INSTITUTE INCBarry Schechter, MD, is the Director of Department of Cornea and External Disease at Florida Eye Microsurgical Institute. Dr. Schechter's practice involves diseases of the ocular surface including dry eyes, allergies, infection; the latest in corneal,...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
The good news is that these drugs are already approved
October 28, 2009
Triple-combo Drug Shows Promise Against Antiviral Resistant H1N1 | www.medicalnewstoday.com
Adamas has a proprietary mixture of three drugs: amantadine, oseltamivir and ribavirin to treat antiviral resistant strains of novel H1N1 Influenza A.
-
Starpharma gets US patent for use of VivaGel for protection against STIs
September 29, 2009
Starpharma gets US patent for use of VivaGel for protection against STIs | www.pharmabiz.com
Starpharma's lead product, is a vaginal microbicide gel under development for the prevention of sexually transmitted infections (STIs), including genital herpes and HIV infection. The VivaGel® product concept is designed to offer a safe, convenient and affordable means for women to protect themselves from infection with genital herpes and HIV during sex. Surveys show that there is substantial demand in North America and Europe for such a product with an estimated billion dollar market for STI prevention products in the developed world.
-
Stelara new Option for Psoriasis
September 26, 2009
Stelara Approved to Treat Moderate to Severe Plaque Psoriasis in Adults | www.webmd.com
The FDA approved Stelara based on three studies of 2,266 patients who either got shots of Stelara or a placebo. Patients who got Stelara were more likely to achieve the studies' benchmark for reduction in psoriasis.In a news release, the FDA notes that because Stelara reduces the immune system's ability to fight infections, the product poses a risk of infection. "Serious infections have been reported in patients receiving the product and some of them have led to hospitalization. These infections were caused by viruses, fungi, or bacteria that have spread throughout the body. There may also be an increased risk of developing cancer," the FDA states.
-
Potential game changer for patients and hospitals regarding C. difficile colitis
July 18, 2009
Rapid DNA Test to Detect Clostridium difficile Infection Approved by FDA Today | www.medscape.com
Clostridium difficile-associated colitis is a disabling, and potentially life-threatening infection. Moreover, hospitals spend great resources in isolating patients with this disease to prevent infection within the hospital. This new technology from Cepheid offers faster, and more accurate diagnosis, leading to potentially quicker treatment for patients, but potentially huge savings for hospitals, that can shorten isolation periods for these patients.
-
18 months too late for this outbreak, but may be the way toward the future.
July 8, 2009
Cadila Pharma-Novavax JV to produce swine flu vaccine | www.business-standard.com
The referenced article states that the joint venture would begin producing swine flu vaccine in two years, possibly based on viral-like particle (VLP) technology. While this is too late to have significant impact in the current pandemic, it points to possible future technologies for vaccine development.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Academic Institution*
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Medical Director
- Owner
- Director
- Physician - Division Head
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| HIV Specialists (US) | 367 |
| Cubicin Prescribers (US) | 180 |
| Pathologists (US) | 792 |
| Immunologists (US) | 384 |
| Fuzeon Prescribers for HIV (US) | 43 |
| Council Members who Use the IDI-MRSA assay in the U.S. | 43 |
| Maraviroc Experts | 41 |
| Prescribers of Combivir : HIV Specialists (US) | 33 |
GLG Live Meetings with this Study Group's Leading Experts (?)
January 25, 2008 | Boston
GLGi: Psoriasis and Medical DermatologyFebruary 23, 2007 | New York
GLGi: Emerging Therapies for HIV Grand RoundsGLG Webcasts & Teleconferences
Leading Experts in Infectious Diseases Physicians (US) have not participated in any GLG webcasts.